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Unfortunately, none of the neuroprotectants has been proved effective in clinical trails. In the current study, we demonstrated that methylene blue (MB) functions as an alternative electron carrier, which accepts electrons from NADH and transfers them to cytochrome c, and bypasses complex I/III blockage. A de novo synthesized MB derivative, with the redox center disabled by N-acetylation had no effect on mitochondrial complex activities. MB increases cellular oxygen consumption rates and reduces anaerobic glycolysis in cultured neuronal cells. MB is protective against various insults in vitro at low nM concentrations. Our data indicate that MB has a unique mechanism and is fundamentally different from traditional antioxidants. We examined the effects of MB in two animal models of neurological diseases. MB dramatically attenuates behavioral, neurochemical, and neuropathological impairment in a Parkinson's disease model. Rotenone caused severe dopamine depletion in the striatum, which was almost completely rescued by MB. MB rescued the effects of rotenone on mitochondrial complex I-III inhibition and free radical over-production. Rotenone induced a severe loss of nigral dopaminergic neurons, which was dramatically attenuated by MB. In addition, MB significantly reduced cerebral ischemia reperfusion damage in a transient focal cerebral ischemia model. The present study indicates that rerouting mitochondrial electron transfer by MB or similar molecules provides a novel strategy for neuroprotection against both chronic and acute neurological diseases involving mitochondrial dysfunction.
Mitochondria are the power houses and the major source of free radicals in almost all cells. Mitochondrial dysfunction is implicated in numerous neuropathological diseases, including Parkinson's disease (PD) (1,2), Alzheimer's disease (AD) (3) , and stroke (4) . Other than ATP production, mitochondria participate in diverse cell signaling events and are essential organelles for cell survival. The oxidative phosphorylation machinery is composed of five complexes (complex I-V). From Krebs cycle intermediates (NADH and FADH 2 ), electrons feed into complex I or II, and are transferred to complex III, then to complex IV, and finally to oxygen molecule. Energy released during the electron transfer is utilized to actively pump out proton from the mitochondrial matrix to the intermembrane space, generating the electrochemical gradient of proton across the inner membrane, which is ultimately utilized by complex V to produce ATP (5) . However, a small portion of electrons leaking from the electron transport chain (ETC), mostly at complex I and complex III, react with oxygen molecule and yield superoxide anion, which can be converted into other reactive oxygen species (ROS).
When ROS production overwhelms the endogenous antioxidant systems, they can potentially damage various cellular components, including proteins, lipids, and nucleic acids. ROS is implicated in aging and various pathological processes, and has been proposed as the key culprit for many neurodegenerative diseases. Thus, mitochondrial targeting strategies such as free radical scavengers, mitochondrial signaling regulation, and ETC component supplementation have been extensively studied (6, 7) . Disappointingly, none of these neuroprotective strategies has been proven successful in any neurological diseases in clinical trials (8, 9) .
Methylene blue (MB) is a heterocyclic aromatic compound that has many biological and medical applications. It is an FDA approved drug for methemoglobinemia and an antidote to cyanide poisoning. Previous publications have suggested that MB improves mitochondrial function (10, 11) . In the present study, we demonstrate that MB functions as an alternative electron carrier that efficiently shuttles electrons between NADH and cytochrome c (cyt c). This process reroutes electron transfer upon complex I and III inhibition, reduces electron leakage, and attenuates ROS over-production. MB is protective in a rotenone induced animal model of Parkinsonism and an animal model of ischemic stroke induced by middle cerebral artery (MCA) occlusion.
EXPERIMENTAL PROCEDURES

Animals and reagents:
Male Sprague-Dawley rats (230-250g; approximately ten weeks old) (Charles River, Wilmington, MA) were housed individually with controlled temperature (22-25°C) and humidity (55%). A 12-hour light-dark cycle was maintained, with lights on between 7 a.m. and 7 p.m. All housing and procedures were performed in accordance with the guidelines of the Institutional Care and Use Committee of the National Research Council, and were approved by the University of North Texas Health Science Center Animal Care and Use Committee. Mitochondrial isolation and mitochondrial respiration chain activity assays: Fresh rat heart was removed and placed in ice-cold mitochondrial isolation buffer containing 210 mM mannitol, 70 mM sucrose, 5 mM HEPES, and 1 mM EDTA, pH 7. The heart was homogenized immediately, and the mitochondrial fraction was isolated by differential centrifugation as described previously (12) . Mitochondria were stored at -80 °C until subsequent analysis.
All mitochondrial activity assays were performed according to previous publications with minimal modifications for complex I (13), complex I-III, complex II, complex III, and II-III (12) . All assays used a similar master mix that contained potassium phosphate pH 7.4 (50 mM), BSA 2.5mg/ml, MgCl 2 5 mM, KCN (2 mM), and various inhibitors or substrates, including rotenone (6 M), antimycin A (2 M), NADH (150 M), CoQ1 (60 M), cyto c (50 M), succinate (8 mM), and DBH 2 (100 M). Complex I activity was monitored by adding NADH to the mix with or without rotenone/antimycin A. The final data were normalized to blank values at time zero. The reaction was monitored in a kinetic spectrophotometer at 340 nm. Complex I activity was measured in arbitrary units and normalized to control levels for statistical analysis. Isolated mitochondria equivalent to 40-200 µg mitochondrial protein was used for each assay, except for assays with inhibitors, when higher levels of mitochondria (three to five fold) were used to ensure that inhibition was distinguishable. Final data were normalized to control levels. For complex I-III activity, the reaction was initiated with the addition of NADH, cyto c was used as final substrate and its reduction was monitored at 550 nm. For assay of complex II-III activity, succinate was added instead of NADH, and the electron transfer to cyto c was performed according to previous publication (10) . To test whether the electrons from the reduced form of MB (MBH 2 ) can be transferred to cyto c in mitochondrial lysate, we added 10 M 2,7-dichlorofluorescin (DCFH, Invitrogen, Carlsbad, CA) to the reaction system. Free radicals convert non-fluorescent DCFH to highly fluorescent DCF (Ex, 488 nm, and Em, 530 nm). In the presence of cyto c, which accepts electrons from MBH 2 , conversion of DCFH to DCF is decreased. Cell viability assay: HT-22 cells (gift from Dr. David Schubert, Salk Institute, San Diego, CA) were plated at 4,000 cells per well in 96 well plates and cultured over night. Then cells were treated with vehicle (DMSO), rotenone (2-8 M), antimycin A (1-10 g/ml), or glucose oxidase (2-3 10 mU) in the presence or absence of various concentrations of MB for 24 hr. At the end of the 24 hr, the medium was removed and the plates were rinsed with PBS and incubated with 10 M calcein-AM (Invitrogen, Carlsbad, CA) in PBS for 20 minutes. Fluorescence was determined using a TECAN M200 microplate reader (San Jose, CA) with an excitation/emission set at 485/530 nm. Cell culture wells treated with bleach before rinsing were used as blank. Intracellular ATP assay: HT-22 cells were plated in 96 wells at 5000 cells / well, and cultured over night. Vehicle or increasing concentrations of MB were added to the culture medium (N=6-8) and incubated for 4 hr. The ATP determination was performed with ATP determination kit (Invitrogen, Carlsbad, CA). p-trifluoromethoxy carbonyl cyanide phenyl hydrazone (FCCP) and potassium cyanide (KCN) were used as control for inhibition. A standard curve was performed in the same assay plate. Seahorse XF-24 Metabolic Flux Analysis: HT22 cells were plated at 8000/well, and cultured on Seahorse XF-24 plates. Cells were grown in previously described medium and environments for 24 hr. On the day of metabolic flux analysis, cells were changed to unbuffered DMEM (DMEM base medium supplemented with 25 mM glucose, 10mMsodium pyruvate, 31 mM NaCl, 2 mM Glutamine, pH 7.4) and incubated at 37 °C in a non-CO2 incubator for 1 hr. All medium and injection reagents were adjusted to pH 7.4 on the day of assay. Four baseline measurements of oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were taken before sequential injection of mitochondrial inhibitors. Specific readings indicated by the arrows were taken after each addition of mitochondrial inhibitor before injection of the subsequent inhibitors. The mitochondrial inhibitors used were oligomycin (10 M), FCCP (1 M), and rotenone (5 M). OCR and ECAR were automatically calculated and recorded by the Seahorse XF-24 software. After the assays, plates were saved and protein readings were measured for each well to confirm equal cell numbers per well. The percentage of change compared with the basal rates was calculated as the value of change divided by the average value of baseline readings. Mitochondrial superoxide and cellular ROS analysis: Mitochondrial specific superoxide and cellular ROS were measured with specific fluorescent probes. Briefly, HT-22 cells were treated with vehicle or 2 M rotenone, with or without 100 ng/ml MB for 4 hr. The cells were dissociated, then incubated in pre-warmed PBS containing 0.5% BSA and H2DCFDA (Cellular ROS) or MitoSox (mitochondrial superoxide) for 15 min at 37 °C, followed by washing with PBS. The cells were then resuspended in supplemented RPMI-1640 for further incubation. The cells were analyzed with FITC channel (Cellular ROS), or PE channel (MitoSox) using a BD TM LSRII flow cytometer. Effect of MB on a rotenone model of PD: Rats were assigned to three groups: control animals received vehicle infusion and daily saline injection (Veh/Sal N=6-8); a second group received rotenone infusion at the dose of 5 mg/kg/day, and daily saline injection (ROT/Saline N=8-11); and the third group received rotenone infusion (5 mg/kg/day) and MB injection at the dose of 500 g/kg/day (ROT/MB N=8-10). Vehicle or rotenone was infused via Alzet osmotic mini pumps that were filled with vehicle or rotenone dissolved in vehicle (equal volumes of dimethylsulfoxide and polyethylene glycol). Pumps containing vehicle or rotenone were sterilized with UV irradiation and implanted subcutaneously on the back. Intraperitoneal injections were administered with normal saline or MB, 500 g/kg/day, diluted in normal saline to 500 l of final volume. Rats were sacrificed on day 8 at 4 hours after last dose of MB or saline treatment. Accelerating rotarod performance: The accelerating rotarod (Omnitech Electronics, Columbus, OH) measures running coordination and motor performance. The rotor consisted of a nylon cylinder with a 7 cm diameter mounted horizontally 35.5 cm above a padded surface. On a given trial, the rats were placed on the cylinder, the cylinder was rotated, and a timer switch was simultaneously activated. Acceleration continued from 0 to a maximum of 44 rpm until animals were unable to stay on top of the rotating rod and fell to the padded surface. Animals were removed at 90 seconds if they did not fall. When the rat landed on the surface, a photosensitive switch was tripped and the timer stopped. Rats were subjected to this test two sessions a day, three trials per session, for 7 sessions. A 20 minute resting period was given between each trial. Animals were given at least 2 hours break time between sessions each day. Retention times on the rotating treadmill were recorded and plotted for analysis. Neurological assessment: Neurological assessment was performed by three evaluators blind to treatment conditions. The evaluators were initially trained until they produced consistent scores when evaluating rats in these tests. Subsequently, experimental subjects were randomized and presented to the evaluators individually. For each session, which consisted of three trials, an individual evaluator scored a rat in only one trial; thus, the final score for a session for each animal was the average score of the three evaluators. The category included: tremor; locomotion; bradykinesia; hypokinesia; posture; and gross motor skills. The details on the scoring systems were adapted from previous publications in various animal models including MPTP and 6-OHDA lesions (14, 15 Gross motor skills 0: Able to retrieve small objects accurately 1: Reduced ability/ of retrieving small objects 2 Great difficulties in retrieving small objects 3 Unable to retrieve objects Catalepsy measurement: Catalepsy was measured by standard bar test and grid test adapted from previous publication (16) . For bar test, the rats were placed with both front paws grasp on a horizontal bar which was 9 cm above the surface. The time, each animal took to remove one paw from the bar was manually measured by a stopwatch. The grid test involved placing the rats on a vertical wire grid (25.5 cm width and 44 cm high with a space of 1 cm between each wire) and catalepsy was determined by the length of time the animals maintained all four paws on the grid using a stopwatch. The maximum descent latency was set at 300 seconds for the bar test and 60 seconds for grid test. Gait Analysis for Stride Length: For gait analysis, the fore and hind paws of each rat were painted with blue and red dye, respectively, and the animals were allowed to walk across a absorbent paper covered straight alley runway (150 cm long, 20 cm wide, opaque walls 20 cm tall) into a dark compartment. Before the test, animals were put in the dark compartment for 2 minutes to habituate to the environment and 3 pretraining runs were conducted for all rats. Three trials were conducted to obtain clear footprints for each animal. Prolonged stop or turning backward in the runway was considered failed trials. The distance of individual steps were analyzed by two independent blinded observers. Average of the left and right stride distance for each animal was used for statistical analysis. Tissue collection: After completion of neurological assessments and behavioral tests, rats were killed on the 8 th day of rotenone infusion under anesthesia induced by xylazine (20 mg/kg, i.p.) and ketamine (100 mg/kg, i.p.). All osmotic pumps were checked for the residual liquid to ensure proper drug delivery. The brains were harvested. One hemisphere was fixed by 4% paraformaldehyde in phosphate buffer for 48 hr until processing for sectioning. The other hemisphere was snap-frozen in liquid nitrogen, and kept at -80 ºC until extraction for biochemical analysis. Striatums dissected from a separate set of animals were used for analysis of monoamines by HPLC. Transient cerebral ischemia: Six to eight week old male Sprague Dawley rats (Charles River) were used. Transient cerebral ischemia was induced by an intraluminal filament MCA occlusion model. Briefly, the internal carotid artery (ICA) was exposed, and a 3-0 monofilament nylon suture was introduced into the ICA lumen through a puncture and gently advanced to the distal ICA until proper resistance was felt. After 1 hr, the suture was withdrawn for reperfusion and the distal ICA was cauterized. At 24 hr after reperfusion, the animals were sacrificed and the brain harvested. The brains were sectioned at 3, 5, 7, 9, 11, 13 and 15 mm posterior to the olfactory bulb. Each slice was incubated 30 min in 2% 2,3,5-triphenyltetrazolium chloride (TTC) in physiological saline, then fixed in 10% formalin. The stained slices were digitally photographed for measurement of ischemic lesion volume (ImagePro Plus 4.1). HPLC analysis of monoamines and metabolites: For monoamines and metabolites measurement, striatum tissue was dissected from each hemisphere, weighed, and stored at -80 ºC. For HPLC analysis, tissue samples were sonicated in 9 volumes of 0.1 M perchloric acid containing 0.2 mM sodium metabisulfite and centrifuged at 15,000 rpm for 20 minutes at 4 °C in a benchtop centrifuge to clear debris. Five µl of cleared supernatant was injected onto a C18 HPLC column and separated by isocratic elution at a flow rate of 0.6 ml/min with MD-TM mobile phase (ESA Inc, Chelmsford, MA). Neurotransmitter monoamines and metabolites were detected using an ESA CoulArray electrochemical detector with a model 5014B cell set to a potential of +220 mV. Peak areas were compared to a standard curve of external standards to calculate quantities of dopamine and metabolites per mg tissue. Immunohistochemistry: Rat hemispheres were sequentially incubated in 10%, 20% and 30% sucrose over night. The brains were then frozen in OCT (Optimal Cutting Temperature) compound (VWR, San Francisco CA) and sectioned in the coronal plane with a cryostat to produce 20 μm floating sections. For single immunohistochemistry studies, 20-μm sections were blocked with 5% normal goat serum and incubated in primary antibodies at 4 ºC over night.
Sections were then immunostained with Picture Plus immunohistochemistry kits (Invitrogen, Carlsbad, CA). 3,3´-diaminobenzidine tetrachloride (DAB) was used to visualize the sections. The primary antibodies used include a monoclonal mouse antibody against tyrosine hydroxylase (TH) (1:500) (Millipore, Billerica, MA), a monoclonal anti-ubiquitin (1:800) (Millipore, Billerica, MA), and a monoclonal anti-α-synuclein (1:100) (Santa Cruz, Santa Cruz CA). For fluoro-jade B staining, paraformaldehydefixed brain sections from brains in each group were stained according to the manufacturer's protocol (Millipore Billerica, MA). The slides were first immersed in 1% NaOH in 80% alcohol for 5 minutes, followed by washing for 2 minutes in 70% alcohol and 2 minutes in distilled water. The slides were then transferred to a solution of 0.06% potassium permanganate for 10 minutes to ensure consistent background suppression between sections. The slides were then stained with 0.0004% fluoro-jade B solution for 20 minutes. Double labeling for TH and fluoro-jade B was achieved by immunofluorescence. Sections were initially stained with fluoro-jade B, then, incubated with antibodies against TH for 1 hr at room temperature, and Alexa 594 conjugated goat antimouse IgG was used to detect TH-positive cells. For controls, primary antibodies were omitted. Double stained sections were examined with conventional fluorescence microscopy, and images were captured on a Zeiss microscope linked to an image analysis system with selective filter sets to visualize FITC, rhodamine, and DAPI separately. DAB immunostained sections were visualized with a bright-field microscope, and images were collected with a colored digital camera. Total ROS assay: Frozen brain tissue was placed in 10-fold volume/weight ice cold PBS containing a protease inhibitor cocktail (EMD bioscience Gibbstown, NJ) and homogenized rapidly with a Polytron power homogenizer. An aliquot was ultra-centrifuged at 50,000g for 30 min. Supernatant was removed and analyzed for total ROS content using the fluorescence probe DCFH. DCFH was dissolved in absolute ethanol and diluted with PBS (pH 7.4) to 125 μM, and added to sample brain extracts at a final concentration of 25 μM followed by incubation at 37 °C for 10 minutes. Fluorescence intensity was measured using a fluorometer (TECAN M200 microplate reader San Jose, CA) at an excitation/emission wavelength set of 485/530 nm. Data were presented as relative fluorescent intensity (RFI) or percent of control. DCFH without brain extracts was used as blank and was consistently less than 1% of final fluorescence units. Statistical analysis: The data for mitochondrial complex activity with MB alone, animal body weight, dopamine/5-HT levels and ROS in vivo were analyzed with one-way ANOVA; mitochondrial I-III activity assay with inhibitors, complex II-III assay with inhibitors, and cell viability assays were analyzed by two-way ANOVA (treatment group with concentration); Rotarod assay and neurological assessment were analyzed by three-way ANOVA (group, session/category, and performance). When a significant difference was detected by ANOVA, a post hoc Tukey's test was performed to identify a specific difference between groups. Values were expressed as mean  standard error of mean (SEM). Between two indicated samples, student-ttests were used to acquire P value. The p value < 0.05 was used to indicate statistical significance. In all assays * indicates (P<0.05), ** indicates (P<0.01), and *** indicates (P<0.001).
RESULTS
MB
increases cellular oxygen consumption rate and reduces anaerobic glycolysis. MB has been previously reported to improve mitochondrial functions. In our initial experiments, we used Seahorse Cellular Bioenergetic analyzer to examine the effects of MB on mitochondrial respiration and cellular glycolysis in transformed hippocampal HT-22 cells. Oligomycin (complex V inhibitor), FCCP (uncoupler), and rotenone (complex I inhibitor) was sequentially applied to determine the action of MB on the ETC. MB rapidly increased OCR despite of all treatments (Fig. 1A) . With 2 hours incubation, MB dose-dependently increased OCR from 264 ± 10 pmol/min with vehicle treatment to 594 ± 19 pmol/min with 10 g/ml MB treatment (Fig. 1B) , and reduced ECAR from 44 ± 4 mPH/min with vehicle treatment to 9 ± 3 mPH/min with 10 μg/ml MB treatment (Fig. 1C) . In addition, MB dose-dependently attenuated rotenone induced OCR inhibition (Fig. 1D) . We determined the effect of MB on ATP production (Fig 1E) . Four hours MB treatment significantly increased cellular ATP levels in the HT-22 cells, which peaks at 1 ng/ml (3.34 nM). We used two control compounds: a potent oxidative phosphorylation uncoupler, FCCP, and a complex IV inhibitor, KCN. FCCP increases OCR, while KVN reduces OCR. However, both compounds significantly reduce intracellular ATP levels.
MB directly improves ETC I-III activity and protect against complex I and III inhibition. We analyzed the effects of MB on the overall activity of mitochondrial ETC complex I-III in extracted mitochondria. MB dosedependently enhanced mitochondrial complex I-III activity, as evidenced by the enhanced electrons transfer from NADH to cyt c. An up to 9-fold increase of complex I-III activity was detected in the presence of increasing doses of MB (0.1-1 g/ml) ( Fig. 2A-B) . As a proof-of-concept for the mechanism, we modified MB with N-acetylation. This acetylation blocked the redox capacity of MB, and completely eliminated the action of MB on complex I-III (Fig. 2B-C) . Similar assays were performed in the presence of a specific complex I inhibitor (rotenone) (Fig. 2D ) and a specific complex III inhibitor (antimycin A) (Fig. 2E) . A 90% and 70% inhibition of complex I-III activity was induced by rotenone and antimycin A, respectively. MB treatment dose-dependently prevented the inhibitory action of rotenone and antimycin A. Specifically, 1 g/ml MB increased I-III activity to 118.1  6.4% of control in the presence of rotenone (Fig. 2D) . MB (1 g/ml) increased such activity to 674  99% of the control level in the presence of antimycin A (Fig. 2E) . On the other hand, MB had no significant effects on complex II-III activity, for which 80% of activity was inhibited by antimycin A (Fig 2F) . These data demonstrate that MB is actively involved in the electron transfer process in mitochondria between complex I and complex III.
MB forms a redox cycle between NADH and cyt c that re-routes electrons between complex I and III. We further examined the effects of MB on individual mitochondrial complex I, II, and III activities. MB had no significant effect on complex II or complex III activity alone (data not shown). However, we found that MB was a direct substrate of NADH dehydrogenase in mitochondrial complex I. In a typical complex I activity assay, CoQ1, an endogenous substrate for complex I, was used to receive the electrons from NADH. This enzymatic reaction was very sensitive to rotenone (above 95% inhibition). Our results indicate that MB can act as an independent substrate to accept the electrons from NADH, and convert MB to the reduced form (MBH 2 ), without the involvement of other physiological intermediates, such as Co-Q1 (Fig. 3A,C) . Such activity is relatively insensitive to rotenone inhibition (26.7% at maximum rotenone concentrations). We also observed that electrons from reduced MB (MBH 2 ) can be further delivered to cyt c in a competitive manner (Fig.  3B,D) . In this experimental setup, DCFH was used as a probe to monitor electron transfer. Without cyt c, MB facilitated the electron transfer from NADH and enhanced the oxidation of DCFH probe. In the presence of cyt c, MBH 2 transferred electrons to cyt c instead of DCFH, leading to a decrease in DCFH oxidation. The addition of cyt c significantly decreased oxidation of the DCFH in a dose-dependent manner (Fig. 3,B-D) , suggesting that the reduced form of MB (MBH 2 ) is able to deliver the electrons to cyt c in mitochondria.
MB protects against rotenone-and antimycin A-induced cytotoxicity, and decreases mitochondrial superoxide and cellular ROS production under stress. We examined the effects of MB treatments on mitochondrial oxidative phosphorylation inhibition in HT-22 cells. A significant protective action of MB against complex I inhibition (rotenone) toxicity was seen at all rotenone concentrations examined. At the highest rotenone concentration (8 M), cell survival increased from 25.4  1.6 % with vehicle co-treatment to 60.5  4.5 % survival with 100 ng/ml MB co-treatment (Fig. 4A ). Significant protection was also found with MB against complex III inhibitor (antimycin A) at various concentrations. At the highest antimycin A concentrations tested (25 g/ml), 19.4  3.0% cells survived without MB, while 80.3  9.6 % cell survival was observed with MB at 10 ng/ml (26. 7 nM). A complete protection was found for MB at 100 ng/ml (267 nM) (Fig. 4B) .
We further examined whether MB could function as a direct ROS scavenger. Glucose oxidase chronically oxidizes glucose in the medium to release H 2 O 2 , which results in cell death. MB failed to protect cells with such H 2 O 2 induced oxidative damage (Fig. 4C) . In contrast to these results with H 2 O 2 , MB (100 ng/ml) almost completely blocked the increase in mitochondrial superoxide (MitoSox) and total cellular ROS (DCFH 2 -DA) production when rotenone was used to induce mitochondrial specific superoxide and ROS production in HT-22 cells (Fig. 4D-E) . Unlike many other antioxidants, MB is not an ROS scavenger, rather, it decreases the production of ROS by improving mitochondrial function.
MB attenuates neurological and behavioral deficit in a rat model of PD. We used systemic rotenone infusion to produce a rat model of PD. The effects of MB in this model were determined by neurological and behavioral assessment, biochemical analysis, and neuropathological evaluation. Rats treated with rotenone endured significant weight loss, which was attenuated by MB treatments (Fig. 5A ). Significant locomotor deficits were found in rotenone treated rats (Fig. 5B) . In rotarod tests, control rats receiving vehicle showed improved performance in early sessions. In contrast, the rotenone-treated group showed decreased performance from the beginning of the sessions (5 th day after rotenone infusion), and had lower performance throughout the sessions. MB treatment almost completely prevented these rotenone-induced locomotor deficits (Fig. 5B) . In randomized blinded neurological assessment, significant deficits in all categories were observed in rotenone-treated animals, evidenced by the higher score at each assessment. MB treatment significantly improved all neurological scores in rotenone treated rats (Fig. 5C) .
Catalepsy was tested by measuring the descent latency after 5 days of rotenone infusion, using both bar and grid tests. In both tests, rotenone-treated animals showed marked deficiency, which was significantly improved by MB treatment. Specifically, rotenone prolonged descent latency in bar test as comparing to control animals, and MB treatment completely reversed such change induced by rotenone (Fig. 5D) . Similarly, in grid test, rotenone significantly decreased latency to fall, which was attenuated by MB treatment (Fig. 5E) . In gait analysis, rotenone significantly decreased stride length, which was improved by MB treatment (Fig. 5F ). We analyzed the levels of dopamine, dopamine metabolites, and 5-HT in striatum. Dopamine levels (Fig. 6A) as well as its metabolite, 3,4-Dihydroxyphenylacetic acid (DOPAC) (Fig. 6B) , significantly decreased in striatum derived from rotenone-treated group (ROT/Sal), compared with the control group (Veh/Sal). Consistently, such dopamine depletion was almost completely rescued by MB treatment (Fig. 6A-B) . Interestingly, there was no significant difference in 5-HT levels among all three groups of animals (data not shown). These results confirmed the selective toxicity in dopaminergic system induced by rotenone. We also assayed the mitochondrial activity in the brain extracts. A significant decrease of complex I-III activity was found in the ROT/Sal group, which was prevented by MB treatment (Fig. 6C) . We interpret this as the result of ROS-induced complex I/III damage, as previous publications suggested that complex I/III is the most sensitive component in the oxidative phosphorylation chain during stress (17,18). We also measured overall ROS in the brain extracts, and found that the ROT/Saline group had a significantly higher level of ROS compared to control groups. The increase of ROS by rotenone was also attenuated in the ROT/MB group (Fig.  6D) .
MB attenuates dopaminergic neuron degeneration induced by chronic rotenone infusion. We used histological analysis for classical PD pathology. In the ROT/Sal group, inhibition of complex I resulted in degeneration of nigrostriatal dopaminergic neurons (Fig. 7) . With this dose and duration of rotenone exposure, animals demonstrated severe loss of dopaminergic neuron at the substantia nigra pars compacta, together with varying degrees of striatal dopaminergic denervation (data not shown). Animals with dopaminergic neuron degeneration in substantia nigra were variable and correlate to their individual behavioral performance. Near complete loss of tyrosine hydroxylase (TH)-positive cells in substantia nigra was observed in 5 out of 11 rotenone-treated animals with the remaining showed varying degrees loss of TH positive cells. Furthermore, TH staining of the ventral tegmental area (VTA) showed remarkable nerve fiber degeneration in ROT/Sal treated animals, a similar finding as observed in previously (2) . On the other hand, in the ROT/MB animals, a sufficient amount of TH-positive cell and nerve fiber were observed in SNC and VTA, respectively (Fig. 7) . In addition, ubiquitinpositive cytoplasmic inclusions were observed in rats with dopaminergic neuron degeneration. Such inclusions were frequently clustered in the cytoplasm of ubiquitin-positive cells, similar to those seen in Lewy bodies. In our study, 6 out 11 ROT/Sal rats showed ubiquitin positive aggregates, while such inclusion bodies were not found in any of the animals in the control group or the ROT/MB groups (Fig. 7) .
To confirm that the loss of TH staining in dopaminergic neurons and nerve terminals was due to neurodegeneration, fluoro-jade B histochemistry was performed in brain sections from these animals. Fluoro-jade B-positive TH neurons were not found in either Veh/Sal group or the ROT/MB group. In contrast, fluoro-jade Bpositive neurons were observed in the substantia nigra areas in 4 out of 11 ROT/Sal animals (Fig.  8) . We further examined the fluoro-jade B positive cells with double labeling of TH (Fig. 8) (Fig. 9A) . By rerouting electron transfer which bypasses complex I and III blockage, a single dosage of MB at 500 g/kg significantly reduced the ischemic lesion volume (Fig. 9B & C) .
DISCUSSION
Neuroprotection is a therapeutic approach that aims to prevent or attenuate neuronal degeneration and loss of function in neurological diseases. Neuroprotective strategies, including but not limited to free radical scavengers, ion channel modulators, and anti-inflammatory agents, have been extensively explored in the last two decades (19) . Unfortunately, despite promising results from preclinical studies, outcomes of clinical neuroprotection trials have been repeatedly disappointing (8, 20) . Increasing evidence has indicated that mitochondrial dysfunction is a common pathological mechanism that underlines many neuropathological conditions. Endogenous ETC component supplementation such as coenzyme Q10 was explored for their neuroprotective effects (21, 22) . In addition, other identified neuroprotectants such as estrogen have been found to increase gene expression for many key components of the ETC complexes (23) . However, the consistent failure of all these approaches has cast doubt on the current neuroprotective strategies. In the present study, we identified alternative mitochondrial electron transfer as a novel neuroprotective strategy. The alternative electron transfer through MB redox cycle bypasses the inhibition of ETC complex I and III, avoids over production of free radical, hence provides neuroprotection in both chronic and acute neurological diseases.
Current evidence suggests that it is not the mitochondrial energy defect per se, but rather the over production of ROS induced by blockage of mitochondrial complexes that accounts for the neurodegeneration in many neuropathological conditions (24) (25) (26) . In fact, cells can survive via many alternative mechanisms other than mitochondrial oxidative phosphorylation, such as anaerobic glycolysis and autophagy. In our observation, complex IV (KCN) or complex V (oligomycin) inhibition reduces cell growth, but does not convey direct cytotoxicity. Previous studies indicate that complex IV/V is not involved electron leakage and ROS production (27, 28) . We found that inhibition of complex IV/V induced anaerobic glycolytic activity and lactate production, which compensated for the decrease of ATP production (data not shown). On the other hand, complex I/III blockage directly cause the leakage of electrons, which react oxygen molecules, lead to ROS generation, and induce cytotoxicity. Thus, an alternative electron transfer pathway can bypass complex I/III blockage, avoid ROS production, and provide neuroprotection.
MB has a very low redox potential of 11 mV and is very efficient cycling between oxidized and reduced forms (10) . In the current study, we determined the action of MB in ETC complex activities. Our results demonstrated that MB functions as an alternative electron carrier similar to the endogenous CoQs in mitochondrial ETC. On the other hand, MB-mediated electron transfer is insensitive to either rotenone or antimycin A inhibition, suggesting that MB provides an alternative route for electron transfer. Upon the completion of the redox cycle (MBMBH 2 MB), electrons from NADH are delivered to cyt c in an alternate route that is insensitive to complex I and III blockage. Such mechanism is further confirmed by a de novo synthesized MB derivative with the disabled redox center by N-acetylation. Acetyl-MB completely lost its ability to enhance electron transfer between complex I and III. The alternative electron transfer through MB prevents the "electron leakage" induced by complex I/III inhibition, and avoids the massive ROS production during complex I/III inhibition (Fig. 10) .
In cell cultures, MB provides protection against mitochondrial inhibition induced ROS over-production, mitochondrial dysfunction, and cytotoxicity. Given the high enzymatic efficacy and potency, the alternative electron transfer strategy requires much lower concentrations for neuroprotection as comparing with the traditional free radical scavengers. Consistently, the neuroprotective effects of MB occur at very low concentrations with an EC50 of 0.1762 nM against glutamate toxicity in HT22 cells. Therefore, the alternative electron transfer strategy is fundamentally different from traditional free radical scavenger approach. Rather, it avoids the production of ROS by re-routing electron transfer and bypasses complex I/III inhibition. Indeed, MB failed to provide protection against direct hydrogen peroxide insult even with much higher concentrations.
We further determined the effects of this novel neuroprotective strategy in animal models of PD and ischemic stroke. From both epidemiological (29) and basic research (2, 30) , growing evidence has indicated that complex I dysfunction is the primary factor in PD pathogenesis. It has been known that complex I activity is deficient in the brain as well as peripheral system in PD patients (reviewed in (24, 26, 31, 32) ). Such concepts are further proved by the recently developed rotenone PD model (2, 33) . Many features of PD have been observed in systemic rotenone model, including complex I impairment (2), oxidative damage (34), accumulation and aggregation of alpha-synuclein in select dopaminergic neurons, and impairment of nigral ubiquitin-proteasome system (UPS) function with accumulation of poly-ubiquitinated proteins (2) . Moreover, two genetic causes of PD, mutations in Parkin and PINK1, have been associated with defective complex I activity (1, 35) . Consistently, over expression of NDI1, a yeast gene encoding a single subunit rotenoneinsensitive NADH-quinone oxidoreductase, in rodents could prevent respiratory deficiencies and attenuates Parkinson-like symptoms in animals treated with rotenone or MPTP (36) . Our in vivo studies indicated that MB attenuates complex I inhibition induced neurodegeneration in dopaminergic neurons, and provides protection against rotenone-induced Parkinson-like behavioral, neurochemical, and neuropathological features.
The role of ROS in the pathogenesis of cerebral ischemia reperfusion injury is well known. Reperfusion produces a burst in ROS formation after cerebral ischemia and has been known as one for the major mechanisms by which reperfusion worsens ischemic damage (37) . Antioxidant has been viewed as one of the most promising neuroprotective strategy for the treatment of ischemic stroke. However, the failure of SAINT II trail has raised concerns regarding the traditional free radical trapping strategy (38) . Instead of neutralizing the free radical, the alternative electron transfer strategy block the over production of ROS generated by the inhibition of ETC complex I and III. In addition, our study demonstrated that MB increases oxygen consumption rate and decreases extracellular acidification rate, which could potentially prevent the superoxide production derived from the excessive oxygen supply during the reperfusion. Consistently, our in vivo study demonstrated that MB, as an alternative electron carrier, significantly decreased the cerebral ischemia reperfusion damage induced by transient focal cerebral ischemia.
There are other considerations for the role of alternative electron transfer in mitochondrial functions. The mitochondrial ETC removes electrons from an electron donor (NADH or FADH 2 ), and passes them to a terminal electron acceptor (O 2 ) via a series of redox reactions. These reactions are coupled to the creation of a proton gradient across the mitochondrial inner membrane, which functions as the direct driving force for ATP synthesis. In ETC, complex I, III, and IV functions as the proton pumps. An alternate route to ETC could bypass the proton pump function in these complexes, and might reduce the efficiency of ATP production. However, our study demonstrated that MB could enhance ATP production, suggesting that MB does not comprise the function of complex I/III/IV as proton pumps.
In addition to the capacity as an alternative electron carrier, many other functions of MB have previously been described. It was shown that MB can delay senescence and extend the life span of human IMR90 fibroblasts in tissue culture (10) . It has also been indicated that MB can penetrate the blood brain barrier, increase cyt c oxidase (complex IV) activity, improve cognitive function in rats (39) , and protect against methylmalonate-induced seizures (40) . As a century-old drug, MB has been in medical use for many years in various pathological conditions (41, 42) . The therapeutic potential of MB has been demonstrated in clinic against many diseases including endotoxin-induced lung injury, bacterial lipopolysaccharide-induced fever (43-45), cyclosporine-induced kidney injury (46), doxorubicin-induced heart injury (47), and pancreas injury induced by streptozotocin (48) . Recently, MB was reported to attenuate tau aggregation, and it is currently in phase II clinical trials for treatment of Alzheimer's disease. Many other activities have also been demonstrated with MB, including inhibition of NOS (49, 50) and monoamine oxidase A (MAO A) (51) , which may also contribute to the illustrated neuroprotective action. However, some of these functions might be secondary to the currently described mitochondrial mechanism and warrants further investigation. In summary, we have identified a novel neuroprotective strategy represented by MB in the present study. We have demonstrated that MB could function as an electron carrier and provide an alternative electron transfer along ETC, avoid ROS over production induced by ETC blockage, maintain mitochondrial function. We have tested this novel neuroprotective strategy in two animal models of neurological diseases. In an animal model of Parkinsonism, MB was able to attenuate rotenone-induced motor deficits and nigraldopaminergic neuronal degeneration. In an ischemic stroke model, MB significantly reduced cerebral ischemia reperfusion damage. Considering that MB has been in clinical use for over a century with few known side effect, the identified novel neuroprotective strategy of alternative electron transfer is now be ready for test in clinical settings, and might lead to the discovery of promising treatments for the mitochondria dysfunction related neurological diseases, such as PD and stroke. 3 ), X-axis depicts fluorescent intensity. Shown is the representative result from three independent sets of experiments. 
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